Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Gene Profiling Essential Tool for Treatment Tailoring

March 7th 2020

Gene profiling assays can accurately and reproducibly assist decision making for patients with hormone receptor-positive breast cancer, with the ultimate goal of improving outcomes or avoiding toxicity.

CDK4/6 Inhibitors Reach New Benchmarks in Overall Survival in HR+ Breast Cancer

March 6th 2020

The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings.

Can We Use Genomic Profiling Data to Influence Locoregional Treatment Decisions in Breast Cancer?

March 6th 2020

Given the solid correlation between the risk of locoregional recurrence (LRR) and distant recurrence, several investigators have examined whether genomic assays that predict risk of distant recurrence can also predict risk of LRR.

Dr. Connolly on Potential Benefit of Postmastectomy Radiation for Breast Cancer

March 5th 2020

Eileen Connolly, MD, PhD, discusses the possible benefit of postmastectomy radiation for patients with breast cancer.

NEJM Data Highlight Neoadjuvant Pembrolizumab Benefit in TNBC

March 3rd 2020

The neoadjuvant combination of pembrolizumab plus chemotherapy led to a higher pathological complete response rate compared with placebo/chemotherapy in patients with early triple-negative breast cancer, across various patient subgroups.

Dr. Wright on Key Strategies in Using Radiation in Breast Cancer Treatment

March 3rd 2020

Jean Wright, MD, discusses key strategies in using radiation therapy to treat patients with breast cancer.

Key Questions Surround CDK4/6 Inhibitors in HR+ Breast Cancer

February 28th 2020

During a recent OncLive Peer Exchange®, a panel of experts sought to answer several key questions regarding the management of advanced, hormone receptor–positive breast cancer, particularly with CDK4/6 inhibitors.

Breast Oncologists Aim to Address Key Unanswered Questions With Novel Research Efforts

February 26th 2020

Experts from Virginia Cancer Specialists, Georgetown University, Dana-Farber Cancer Institute, and Johns Hopkins Medicine to provide insight on some of the pivotal research being conducted at their respective institutions.

Nodal Involvement Impacts Surgical Management of Axilla in Breast Cancer

February 19th 2020

Hernan Vargas, MD, FACS, discusses the criteria that are used to determine the appropriate surgical intervention for patients with node-positive breast cancer and shared questions that still need to be addressed in the space.

Tailored RT Approaches Poised to Alter Treatment in Early-Stage Breast Cancer

February 18th 2020

Jean Wright, MD, discusses the evolution of radiation oncology in early-stage breast cancer and how novel radiation modalities are poised to transform the field.

Dr. Hamilton on the Results of the KATHERINE Trial in HER2+ Breast Cancer

February 14th 2020

Erika P. Hamilton, MD, discusses the superiority of ado-trastuzumab emtansine (T-DM1; Kadcyla) in the phase III KATHERINE study.

Frontline Pembrolizumab/Chemo Combo Improves PFS in PD-L1+ Metastatic TNBC

February 12th 2020

The frontline combination of pembrolizumab and chemotherapy significantly improved progression-free survival compared with chemotherapy alone in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1.

Dr. Lynce on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC

February 12th 2020

Filipa Lynce, MD, discusses the FDA approval of atezolizumab plus nab-paclitaxel for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1

NewYork-Presbyterian/Columbia University Breast Cancer Faculty Share 2020 Resolutions to Improve Patient Care

February 7th 2020

Faculty from NewYork-Presbyterian Hospital/Columbia University Irving Medical Center share their resolutions for the new year and the efforts being made to improve patient outcomes in practice.

Dr. Singh on Dose Dense ACTHP in HER2+ Breast Cancer

February 7th 2020

Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.

Dr. Neven on the Design of the MONALEESA-3 Trial in Advanced Breast Cancer

February 7th 2020

Patrick Neven, MD, outlines the design of the phase III MONALEESA-3 trial in hormone receptor–positive, HER2-negative advanced breast cancer.

Immunotherapy Continues to Show Promise in TNBC

February 6th 2020

Rita Nanda, MD, discusses ongoing advances with immunotherapy in triple-negative breast cancer, as well as develops in the HER2-negative breast cancer paradigm.

Dr. Accordino on the Utility of CDK4/6 Inhibitors in HR+/HER2

February 6th 2020

Melissa K. Accordino, MD, MS, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Research Efforts Continue With Radiation Therapy in Breast Cancer

February 6th 2020

Eileen Connolly, MD, PhD, reflects on novel radiation techniques, as well as ongoing research and challenges with radiation therapy in breast cancer.

Dr. Burris on Investigational Approaches in TNBC

February 5th 2020

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019-2020 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses investigational immunotherapy approaches in triple-negative breast cancer (TNBC).